Showing 1 - 18 results of 18 for search 'Carrier Strike Group 3', query time: 0.13s Refine Results
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6

    Childhood Rheumatic Diseases and COVID-19 Pandemic: An Intriguing Linkage and a New Horizon by Fatih Haşlak, Mehmet Yıldız, Amra Adrovic, Kenan Barut, Özgür Kasapçopur

    Published 2020-07-01
    “…Several days later, causative viral agent was analyzed with deep sequencing and indicated as a novel coronavirus, officially named 2019 novel coronavirus (2019 nCoV) (3). Coronavirus Study Group (CSG) of the International Commission on Virus Classification named this novel coronavirus “Severe Acute Respiratory syndrome Coronavirus 2 (SARS-CoV-2)” on February 11, 2020 and on the same day, the World Health Organization (WHO) named the disease caused by SARS-CoV-2, “Coronavirus disease-2019 (COVID-19)” (4). …”
    Get full text
    Article
  7. 7

    Biodegradable Silk Fibroin Nanocarriers to Modulate Hypoxia Tumor Microenvironment Favoring Enhanced Chemotherapy by Li Bin, Yuxiao Yang, Feiyu Wang, Rong Wang, Hongxin Fei, Siliang Duan, Linling Huang, Na Liao, Shimei Zhao, Xinbo Ma

    Published 2022-07-01
    “…Eventually, SF-based targeted drug carrier provides biocompatibility to reverse hypoxia microenvironment in vivo for enhancing chemotherapy, strikingly suppressing tumor development, and thereby suggesting a promising candidate for drug delivery system.…”
    Get full text
    Article
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12

    <i>CHEK2<sup>p.I157T</sup></i> Mutation Is Associated with Increased Risk of Adult-Type Ovarian Granulosa Cell Tumors by Peter Švajdler, Peter Vasovčák, Marián Švajdler, Monika Šedivcová, Veronika Urbán, Michal Michal, Roman Mezencev

    Published 2022-02-01
    “…Our review of 78 female heterozygous carriers of these mutations (age > 18 years) found strikingly higher proportion of adult-type granulosa cell tumors of the ovary (AGCTs) among ovarian cancers that developed in these women (~36%) compared to women from the general population (1.3%). …”
    Get full text
    Article
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17

    The effects of APOE on brain activity do not simply reflect the risk of Alzheimer's disease. by Trachtenberg, A, Filippini, N, Cheeseman, J, Duff, E, Neville, M, Ebmeier, K, Karpe, F, Mackay, C

    Published 2012
    “…We used functional magnetic resonance imaging (fMRI) to compare the pattern of activation during an episodic encoding task and during a counting Stroop task in 76 adults, aged 32 to 55, with different APOE genotypes (23 ε2/ε3, 20 ε33, 26 ε3/ε4, and 7 ε4/ε4). Strikingly, participants with an increased risk (ε4 carriers) and with a decreased risk (ε2 carriers) for AD both showed increased activation, relative to ε3 homozygotes, during both tasks. …”
    Journal article
  18. 18

    Herpesviruses in brain and Alzheimer's disease. by Lin, W, Wozniak, M, Cooper, R, Wilcock, G, Itzhaki, R

    Published 2002
    “…In 59% of the AD patients' brains harbouring HHV6, type B is present while 38% harbour both type A and type B, and 3% type A. HSV2 is present at relatively low frequency in brains of both AD patients and normals (13% and 20%), and CMV at rather higher frequencies in the two groups (36% and 35%); in neither case is the difference between the groups statistically significant. …”
    Journal article